A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 700 participants.

Also called NCT06679946

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 700 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06679946
  • EudraCT 2024-516568-27
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Austria, Belgium, Brazil, Czechia, Denmark, France, Italy, Netherlands, Norway, Portugal, South Korea, Spain, Sweden, Taiwan, United Kingdom (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT06679946. Allocation not applicable; no masking; primary purpose treatment. Start 2024-12-03 (actual); primary completion 2028-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Condition
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intervention (Drug)
Vutrisiran
Lead sponsor
Alnylam Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06679946
Content hash
8a9a0da902607392bb9f4ba01638b76fbacf2e2d2121260ec127c699f58668c6